August 20, 2018

Dear Kathleen,

This is an update of the memo issued April 3, 2012, clarifying fees charged for the initial and continuing review of Industry Sponsored Clinical Trials. In light of new administrative and procedural requirements, the University has put in place an updated fee structure. For relevant new contracts received on or after September 1, 2018, the initial protocol review fee is set at $2,800, and the continuing review fee at $1,250.

The continuing review fee will be collected annually at the anniversary date of the protocol’s initial approval, for as long as the protocol is active. Nonprofit foundations, voluntary health organizations, government sponsors, and all protocol modifications continue to be exempt from the IRB fee.

Please note: these fees are only applicable to industry sponsored clinical trials, including those reviewed by an sIRB (the IRB of another institution, organization, or an independent IRB). Stanford's IRB bears responsibility for the local conduct of sIRB studies, managing reliance agreements, handling study specific issues, managing noncompliance and unanticipated problems, ensuring training, and study monitoring.

RCO is available for questions should they arise from investigators or sponsors.

Sincerely,

Ann M. Arvin, MD

Kathy McClelland

cc: Monique Bertrand
    Elizabeth Anderson